Psilocybin
Revive Therapeutics Gets Nod From FDA, Could Conduct Psilocybin Study Trials In 2023
Oral psilocybin film-strips to treat could conduct the first-in-human clinical study as soon as next year.
The post Revive Therapeutics Gets Nod From FDA,…
A life sciences company developing dissolvable, oral psilocybin film-strips to treat could conduct its first-in-human clinical study as soon as next year.
On Friday, Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) gave an update on the company’s Phase I/II clinical study of oral psilocybin to treat mental illness, substance abuse, and neurological disorders.
Prototypes of the oral psilocybin thin film strip product have been developed and are being optimized for use in upcoming IND-enabling studies.
“We intend to advance the development of our oral psilocybin thin film strip product for these indications,” said Derrick Welsh, COO of Psilocin Pharma, a division of Revive.
The company has initiated the product development program under a feasibility agreement with LTS Lohmann Therapie-Systeme AG, a leader in pharmaceutical oral thin films, to develop and manufacture a proprietary oral psilocybin thin film strip product for mental illness, substance abuse, and neurological disorders.
“In parallel, we are working on our first clinical study evaluating oral psilocybin in the treatment of methamphetamine use disorder to validate its use in substance abuse indications,” Welsh added.
The company has been evaluating the use of oral psilocybin as a potential treatment for methamphetamine use disorder with the University of Wisconsin-Madison’s School of Medicine and Public Health and School of Pharmacy.
The Phase I/II clinical study looking at the safety and utility of psilocybin in adults with methamphetamine use disorder received both FDA and Institutional Review Board approval.
The clinical data that is generated from the study will provide proprietary and valuable information on the safety, efficacy, and dosing of oral psilocybin to support future pivotal FDA clinical studies for the company’s proposed oral psilocybin thin film strip product.
In addition, the company will have exclusive access to the intellectual property moat from this study to support development, regulatory and commercial initiatives.
“The clinical data from this study will be used to support late-stage clinical trials with our oral psilocybin thin film strip product,” Welsh said.
The post Revive Therapeutics Gets Nod From FDA, Could Conduct Psilocybin Study Trials In 2023 appeared first on Green Market Report.
psilocybin therapeutics cse revive therapeutics revive fda-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID